These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18724045)

  • 1. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site.
    Zharlyganova D; Harada H; Harada Y; Shinkarev S; Zhumadilov Z; Zhunusova A; Tchaizhunusova NJ; Apsalikov KN; Kemaikin V; Zhumadilov K; Kawano N; Kimura A; Hoshi M
    J Radiat Res; 2008 Sep; 49(5):549-55. PubMed ID: 18724045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
    Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
    Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aml1 gene rearrangements and mutations in radiation-associated acute myeloid leukemia and myelodysplastic syndromes.
    Klymenko S; Trott K; Atkinson M; Bink K; Bebeshko V; Bazyka D; Dmytrenko I; Abramenko I; Bilous N; Misurin A; Zitzelsberger H; Rosemann M
    J Radiat Res; 2005 Jun; 46(2):249-55. PubMed ID: 15988144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
    Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract]   [Full Text] [Related]  

  • 13. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
    Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
    Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radiation associated leukemia and myelodysplastic syndrome].
    Kimura A
    Nihon Rinsho; 2012 Mar; 70(3):431-5. PubMed ID: 22514921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology of leukemia and MDS among atomic bomb survivors in Hiroshima and Nagasaki suggests how abnormal epigenetic regulation contributes to leukemogenesis].
    Inaba T
    Rinsho Ketsueki; 2009 Oct; 50(10):1548-52. PubMed ID: 19915365
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiation-induced and therapy-related AML/MDS].
    Inaba T
    Nihon Rinsho; 2009 Oct; 67(10):1880-3. PubMed ID: 19860183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New mechanisms of AML1 gene alteration in hematological malignancies.
    Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
    Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
    Huang G; Zhao X; Wang L; Elf S; Xu H; Zhao X; Sashida G; Zhang Y; Liu Y; Lee J; Menendez S; Yang Y; Yan X; Zhang P; Tenen DG; Osato M; Hsieh JJ; Nimer SD
    Blood; 2011 Dec; 118(25):6544-52. PubMed ID: 22012064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.